From June 29 to 30, 2023, BIO-PHARM2023 and the grand award ceremony of the Huayi List - 2023 China Biopharmaceutical Industry Value List officially opened in Suzhou. As a full-service Contract Research Organization rooted in China and serving globally, R&G PharmaStudies Co., Ltd. (hereinafter referred to as "R&G") was honored with the "Top 10 Most Influential CRO Enterprises" award due to its high-quality services and excellent reputation over the past fifteen years. Mr. Qiao Yuhang, Senior Operations Director of R&G, attended the conference and accepted the award.
Mr. Qiao Yuhang (fifth from the left), Senior Operations Director of R&G, accepts the award on behalf of the company.
The "Huayi List - 2023 China Biopharmaceutical Industry Value List" selection, initiated by Huayi Research Institute in conjunction with Healife Group, aims to select and discover truly influential and high-growth potential innovative enterprises in the biopharmaceutical field, promoting industrial innovation and development. This selection involves 5 categories: Antibody Drugs, Innovative Therapies, Biotechnology, CRO, and CDMO. Based on the enterprise quantitative growth evaluation standards refined over many years by Huayi Research Institute, combined with essential procedures such as questionnaire surveys, corporate interviews, data analysis, and verification, the evaluation team standardizes and quantifies the dynamic data of the shortlisted biopharmaceutical companies. By assessing multiple dimensions such as competitive factors, commercialization factors, value factors, strategic factors, product factors, and team factors, in-depth evaluations of the industry, sector, and companies were conducted, thereby selecting enterprises with significant industry value for the year, forming an objective third-party industry evaluation list.
R&G is rooted in China and looks globally. For fifteen years, it has continuously delved deeply into the field of pharmaceutical clinical research and development, constantly enhancing its innovation capabilities and technical levels. It has provided science-oriented, full-process clinical research services to nearly a thousand pharmaceutical and device R&D enterprises worldwide, helping numerous pharmaceutical and medical device products, adopting innovative designs and scientific methods, promoting efficient communication with the CDE and FDA, accelerating the market launch of pharmaceuticals and medical devices. This has earned the R&G brand high recognition and evaluation from both within and outside the industry, possessing broad influence and reputation.
We would like to thank the conference organizers for their recognition of R&G. We will take this opportunity to continuously enhance our service capabilities, actively exert the influence of R&G Pharma Group in the industry, and contribute to innovation and development in pharmaceutical research and development.
